Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Shareholder Meeting (April 2020)
29 slides from Bactiguard Holding Ab's shareholder meeting presentation, Apr 28, 2020
Slide 1: CEO comment ahead of the 2020 AGM
CEO comment ahead of the 2020 AGM 28 April 2020 Cecilia Edström, CEO 1
Slide 2: Bactiguard in brief starting 2020
Bactiguard in brief starting 2020 A SW EDISH HIST O RY O F INFECT IO N PRO T ECT IO N G LO BAL MARKET FINANCIAL PERFO RMAN CE ACQ UISIT IO N O F VIG ILENZ 2020 250 95 CAGR ≈15% 198 200 163 75 154 139 150 128 55 98 31 100 22 35 15 12 14 50 15 -5 0 -5 2014 2015 2016 2017 2018 2019 Revenues, SEKm EBITD
Slide 3: Sales growth and profitability 2019
Sales growth and profitability 2019 Full Year 2019 vs 2018 • Revenue Growth of 21% • Stable recurring licensing revenues from BD • Non-recurring new license revenue from Zimmer Biomet • Stable development in BIP revenues • EBITDA 31% • Growth and EBITDA margin in line with financial targets 3
Slide 4: Key highlights 2019
Key highlights 2019 A strong fourth quarter led to all time high in 2019 • New major order from China • Strong growth in sales of our own portfolio in the final quarter • Accumulated increase in license revenues from Becton, Dickinson & Company (BD) • Global expansion with initial license fee from Z
Slide 5: The Covid-19 pandemic
The Covid-19 pandemic Source: https://www.scientificanimations. 5 https://commons.wikimedia.org/w/index.php?curid=86358105
Slide 6: Our mission is to prevent infections and save lives
Our mission is to prevent infections and save lives It’s all about infection prevention and control – our activities so far 2020 6
Slide 7: First ever acquisition of Vigilenz
First ever acquisition of Vigilenz March 02 • Privately-owned, manufacturer and supplier of medical devices and consumables, established in 2002 • Focus on wound management and infection control • Portfolio of products ranging from surgical sutures, mesh, wound wash and dressings, to orthopaedic tra
Slide 8: Donation of infection prevention to China
Donation of infection prevention to China March 04 • In the fight against the Corona virus, Bactiguard donates products for infection prevention to Chinese hospitals • At a market value of over 2 million SEK To help fight the new corona virus and protect the most severely ill patients, we will donat
Slide 9: Bactiguard launches product that protects against Coronavirus
Bactiguard launches product that protects against Coronavirus March 12 HYDROCYN® aqua • A water-based antimicrobial solution with neutral pH • Tests have shown that HYDROCYN aqua® is able to inactivate 100 % of previous strains of corona virus within 15 seconds • According to virus experts at Karoli
Slide 10: Orders at a total value of SEK 20 million in first few days
Orders at a total value of SEK 20 million in first few days March 17 “We are in close dialogue with the Government's national coordinator for the life science industry and relevant authorities to secure the permits required to establish production in our home market as soon as possible. “ • Within t
Slide 11: Bactiguard and Svenskt Industriflyg establish air bridge
Bactiguard and Svenskt Industriflyg establish air bridge March 18 • Between Sweden and Malaysia for protective medical equipment, including the recently launched Hydrocyn® aqua • The virus pandemic has led to a large number of countries closing their borders and transport capacity disappearing 11
Slide 12: Bactiguard starts manufacturing disinfectants in Sweden
Bactiguard starts manufacturing disinfectants in Sweden March 25 • The demand for the disinfectant HYDROCYN aqua® has been high since the launch in beginning of March • To meet the needs in the Swedish and European markets, we will start manufacturing disinfectants at our facility in Tullinge 12
Slide 13: Bactiguard launches BIP Foley TempSensor
Bactiguard launches BIP Foley TempSensor April 01 • The only indwelling catheter that combines continuous temperature monitoring with infection prevention • For patients in intensive care, surgery and other conditions where continuous temperature monitoring is important • Coated with the unique Bact
Slide 14: Changes in demand for medical devices
Changes in demand for medical devices Due to the Covid-19 pandemic Increased demand for: Reduced demand for: • Urgent need of protective equipment • Elective surgery – incl. orthopedics and consumables • Expensive, non-critical tools and • Ventilators, ICU equipment equipment • Basic supplies and co
Slide 15: Infection prevention – an increasingly urgent global issue
Infection prevention – an increasingly urgent global issue 15
Slide 16: Antimicrobial Resistance (AMR)
Antimicrobial Resistance (AMR) A Global Challenge Publication in the Lancet Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China 392 K • 26% needed treatment at intensive care unit (ICU) 317K 4.7M • 59% were diagnosed with sepsis • 31% of patients with inv
Slide 17: Healthcare associated infections
Healthcare associated infections HAI frequency Covid-19 can lead to severe viral sepsis and multi-organ failure. ICU treatment is expected to be at least 14 days, and each day in the ICU increases the risk of acquiring a device-related infection, such as CAUTI, CRBSI, VAP. 1 in every 10 patients wor
Slide 18: The Bactiguard technology is effective and safe
The Bactiguard® technology is effective and safe The galvanic mechanism of action • When in contact with fluids the noble metals create a galvanic effect Gold Au • The different electro potentials of the metals create a micro current Silver Ag Palladium Pd • Prevents microbial adhesion (gram positiv
Slide 19: Clinical evidence
Clinical evidence Continuously strengthening the clinical evidence • >200 million Bactiguard coated catheters used • No reported adverse events associated with the coating • Over 40 clinical studies including more than 100,000 patients • 35% weighted average reduction of symptomatic CAUTI, and over
Slide 20: Ongoing studies – April 2020
Ongoing studies – April 2020 • India study, 1000 surgery patients FOLEY • REHAB Spinalis (Sweden) – chronic use patients • Martini-Klinik (Germany) – prostatectomy patients • CRITIC (Brazil) – ICU all three products CVC • IMPROVE (Danderyd, Sweden) – all patients with CVCs • VITALs (Belgium) – ICU 3
Slide 21: Our business model
& Bactiguard Our business model = = = == = i i i fi » » 21
Slide 22: Market presence
Market presence Europe • Relatively recent market entry • Breakthrough tenders in Sweden • Upscaling activities in Germany • Adding more markets MEA China • Market entry in 2016 • Long term presence, major footprint • Well Lead distribution and license partner • Stable overall development despite si
Slide 23: Current license partnerships
Current license partnerships BD (C.R. Bard) Well Lead Medical • Foley catheters for the US, Japan and UK/Ireland • Foleys, CVCs and ETTs for China • Ambition to accelerate growth in China, while regulatory • Successful partnership since 1995 developments are shifting towards locally produced devices
Slide 24: Major market potential
Major market potential Global Sales 2017 USD million 24
Slide 25: Growth Strategy
Growth Strategy We are contributing to the UN Sustainable Development Goals 2030 SAVE LIVES REDUCE CO ST S REDUCE T HE USE O F ANT IBIO T ICS VALUE Broaden portfolio • Develop new license applications Licensing • Expand BIP portfolio • 1-2 new deals per year • Selective acquisitions BIP portfolio •
Slide 26: Bactiguard enters a new development phase
Bactiguard enters a new development phase In Summary • Infection prevention – an increasingly urgent global issue • Acquisition of Vigilenz provides access to the global market for advanced wound care • Many more opportunities for license partnerships • Our growth strategy is clear • Committed Execu
Slide 27: Questions & Answers
Questions & Answers Cecilia Edström CEO Cell phone +46 72 226 23 28 cecilia.edstrom@bactiguard.se 27
Slide 28: Bactiguard – A Swedish history of innovation
Bactiguard A Swedish history of Innovation 1994 1995 1978 Billy Södervall FDA 510k Patent in the US 2008 starts developing Launch of the Bactiguard BIP Foley technology 2013 Launch of 1990 2005 BIP CVC & BIP ETT Partnership with Bactiguard AB C.R. Bard founded 2014 Share listed on Nasdaq, Stockholm
Slide 29: Experienced Board of Directors
Experienced Board of Directors Proposed resolution to the 2020 AGM Christian Kinch Jan Ståhlberg Prof Anna Martling Thomas von Koch Cecilia Edström Proposed new Chairman Proposed new Board member Major shareholder, CEO of Trill Impact AB, Dean Campus North, Major shareholder, CEO of Bactiguard Board